ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	2.68T +75.5%
Revenue (ttm)	331.68B +21.2%
Net Income	54.99B +58.4%
EPS	2,688.35 +51.1%
Shares Out	20.84M
PE Ratio	47.84
Forward PE	36.92
Dividend	500.00 (0.40%)
Ex-Dividend Date	Mar 30, 2026

Volume	115,832
Average Volume	171,012
Open	128,500
Previous Close	128,600
Day's Range	122,100 - 128,600
52-Week Range	70,800 - 172,100
Beta	n/a
RSI	34.72
Earnings Date	Apr 27, 2026

About ST Pharm

ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. I...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2025, ST Pharm's revenue was 331.68 billion, an increase of 21.16% compared to the previous year's 273.75 billion. Earnings were 54.99 billion, an increase of 58.42%.